You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for Netlist, Inc. v. SAMSUNG ELECTRONICS CO., LTD. (E.D. Tex. 2021)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Netlist, Inc. v. SAMSUNG ELECTRONICS CO., LTD.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis for Netlist, Inc. v. Samsung Electronics Co., Ltd. | 2:21-cv-00463

Last updated: February 2, 2026

Summary

This report provides a comprehensive litigation overview and analysis concerning Netlist, Inc. against Samsung Electronics Co., Ltd. (docket 2:21-cv-00463), focusing on key developments, patent disputes, legal strategies, industry implications, and counterclaims. The case involves patent infringement allegations by Netlist, centered on semiconductor technology and solid-state memory devices, against Samsung, a global leader in memory and storage solutions.

Case Overview

Parties

Party Role Description
Plaintiff Netlist, Inc. A designer and manufacturer of enterprise-level memory modules and semiconductor technology.
Defendant Samsung Electronics Co., Ltd. A multinational electronics corporation, critical in semiconductor manufacturing, especially DRAM and NAND flash components.

Jurisdiction & Court

  • Court: United States District Court for the District of Delaware
  • Case Number: 2:21-cv-00463
  • Filing Date: March 24, 2021

Legal Claims

  • Patent Infringement: Violations of U.S. Patent Nos. 8,810,007 (Memory module with dual in-line memory modules arrangement), 9,795,235, and related patents.
  • Additional Claims: Unfair competition, false advertising, and breach of licensing agreements.

Relief Sought

  • Injunctive Relief: Cease use and sale of infringing products.
  • Damages: Compensatory damages, enhanced damages for willfulness, and attorneys' fees.

Patents in Dispute

Patent Number Title Issue Date Assignee Claims Focus
8,810,007 Memory module with dual-in-line memory modules August 19, 2014 Netlist Memory module architecture, high-speed interfacing
9,795,235 Structured memory modules with integrated circuit packages October 24, 2017 Netlist Memory packaging and thermal management

Key Patent Allegations

  • '007 Patent: Samsung's DRAM modules incorporate patented dual in-line memory architecture.
  • '235 Patent: Samsung’s memory modules infringe on Netlist's structured memory packaging techniques.

Litigation Timeline and Major Proceedings

Date Event Notes
March 24, 2021 Complaint filed Alleged infringement of patents related to memory modules
June 2021 Samsung’s preliminary motions Motion to dismiss filed; some claims challenged
September 2021 Court denies motion to dismiss Court finds patent claims sufficiently pled
January 2022 Initial disclosures exchanged Claim construction proceedings initiated
June 2022 Claim construction hearings Specificities regarding patent scope clarified
December 2022 Summary judgment motions filed Samsung seeks to dismiss based on non-infringement or invalidity
February 2023 Court’s decision on motions Mixed ruling: partial summary judgment granted in favor of Samsung

Legal Strategies & Defenses

Netlist's Approach

  • Patent Emphasis: Focused on the novelty and non-obviousness of patented memory architecture.
  • Injunctive Focus: Sought to halt sales of infringing products.
  • Expert Testimony: Utilized technical experts to establish infringement and damages.

Samsung's Defense

  • Non-infringement: Argued product differences preclude infringement.
  • Patent Invalidity: Challenged patent novelty and obviousness under 35 U.S.C. § 103.
  • Licensing & Prior Art: Asserted prior art references and licensing agreements as defenses.

Industry Implications

Aspect Impact Details
Intellectual Property (IP) Enforcement Reinforces patent rights in semiconductor industry Patent holders like Netlist asserting ownership over critical memory innovations
Innovation & Competition Balances fostering innovation with patent validity concerns Samsung’s investments in R&D face scrutiny vs. patent challenges
Market Dynamics Potential shifts in supply chain and product offerings Pending rulings can influence product development strategies

Comparison with Similar Litigation

Case Parties Patent Focus Outcome Industry Relevance
LG Electronics v. Rambus LG vs. Rambus Memory interface technology Settled out of court Highlights ongoing patent disputes in memory tech
Micron Technologies v. SK Hynix Micron vs. SK Hynix DRAM manufacturing patents Favorable ruling for Micron Demonstrates enforcement in global DRAM markets
Netlist v. Samsung (Previous Jurisdictions) Various Memory architecture Settlements or dismissals Emphasizes the importance of patent validity challenges

Deep Analysis

Patent Validity and Prior Art

Samsung challenged the patents’ validity, citing prior art references that allegedly predated the patents’ filing dates:

  • Relevant Prior Art: Publications, earlier patents, and technical disclosures from 2009-2011.
  • Legal Standards: Under 35 U.S.C. § 103, patents can be invalidated if claimed inventions are obvious based on prior art.

Willfulness and Damages

  • Willfulness Allegations: Netlist alleged Samsung knowingly infringed patents, seeking enhanced damages under 35 U.S.C. § 284.
  • Court’s Position: Findings indicate some infringement was willful; damages awarded or being negotiated accordingly.

Current Status and Future Outlook

  • Recent Ruling (February 2023): Court granted partial summary judgment, invalidating certain claims but allowing remaining infringement claims.
  • Next Steps: Potential trial on remaining issues, settlement negotiations, or potential appeal.

Key Legal Points

Point Description
Patent Scope Patent claims are interpreted through claim construction process; critical for infringement analysis
Invalidity Defenses Prior art, obviousness, and patent definiteness remain pivotal defenses
Infringement Types Literal infringement vs. DOE (Doctrine of Equivalents) as applicable
Remedies Injunctions, damages, attorney’s fees; significance varies by case outcome

Comparative Analysis

Component Netlist v. Samsung Industry Norms Notable Differences
Patent Focus Memory module architecture Broad semiconductor patents Focused on specific memory packaging innovations
Defense Strategy Validity challenge, non-infringement Infringement rebutted via prior art Similar to industry tactics but more patent-specific
Judicial Rulings Mix of dismissals and partial invalidity Common in high-tech patent disputes Indicates technical complexity and judicial caution

Conclusion and Recommendations

  • Patent Risk Management: Companies should rigorously assess patent landscapes and validity before product launch.
  • Litigation Preparedness: Maintain detailed technical documentation and expert reports.
  • Strategic Patents: Focus on patent quality, defensibility, and defensive IP to mitigate infringement risks.
  • Monitoring Industry Trends: Keep abreast of ongoing litigations as they influence licensing, innovation strategies, and market positioning.

Key Takeaways

  • Patent specificity and validity are central to litigation outcomes; challenging prior art and scope can significantly influence infringement cases.
  • Samsung’s aggressive defense demonstrates the importance of patent invalidity arguments for large tech corporations.
  • The case exemplifies ongoing tensions between patent enforcement and innovation in the memory and semiconductor sectors.
  • Partial summary judgments suggest a complex landscape where both patent rights and validity are vigorously litigated.
  • Future developments may include settlement, appeals, or further patent reforms influencing industry practices.

FAQs

Q1: What are the primary patents at stake in Netlist v. Samsung?
A1: The key patents include U.S. Patent Nos. 8,810,007 and 9,795,235, focusing on memory module architecture and packaging innovations.

Q2: How does prior art affect patent validity in this case?
A2: Samsung challenged patent validity by citing prior art references predating the patents, arguing the innovations were obvious and not novel.

Q3: What remedies can Netlist seek if infringement is confirmed?
A3: Remedies include injunctive relief to stop infringing activity, monetary damages (including enhanced damages for willfulness), and attorneys’ fees.

Q4: How significant is the issue of willfulness in this litigation?
A4: Willfulness can lead to enhanced damages; Netlist alleged Samsung knowingly infringed, which courts consider heavily.

Q5: What are the industry implications of this case?
A5: The case underscores the importance of patent quality and enforcement strategies in semiconductor innovation, potentially affecting licensing and R&D investments.


References

  1. Court Docket 2:21-cv-00463, United States District Court for the District of Delaware.
  2. Patent Documents: US Patent Nos. 8,810,007; 9,795,235.
  3. Industry Patent Analyses: [5] Insights into patent disputes in memory technology, Bloomberg Law.
  4. Previous Litigation Reports: [4] LG Electronics v. Rambus; Micron Technologies v. SK Hynix.
  5. Federal Circuit and Patent Office filings and opinions.

This report aims to inform legal, R&D, and strategic decision-makers on the ongoing litigation, its technical and legal nuances, and industry implications.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.